Literature DB >> 6305989

Comparison of the 34,000-Da pp60src substrate and a 38,000-Da phosphoprotein identified by monoclonal antibodies.

M E Greenberg, G M Edelman.   

Abstract

One of the cellular targets of the pp60src tyrosine kinase is a phosphoprotein with a Mr = 34,000 and an isoelectric point of approximately 7.5 (Radke, K., Gilmore, T., and Martin, G. S. (1980) Cell 21, 821-828; Erikson, E., and Erikson, R. L. (1980) Cell 21, 829-836). We report here the preparation of monoclonal antibodies to partially purified 34-kDa protein and to a heretofore unrecognized phosphoprotein that is not a pp60src target. Two antibodies were initially obtained that recognized phosphoproteins in the Mr = 34,000-39,000 range. One of these antibodies immunoprecipitated a 34,000-Da protein which, on the basis of its molecular mass, phosphorylation state, and isoelectric point, was determined to be the 34-kDa pp60src substrate. The second monoclonal antibody bound to a 38,000-Da nucleolar associated protein, which appeared not to be a target of the pp60src kinase and was found by tryptic analysis to be structurally unrelated to the 34-kDa protein. The monoclonal antibody to the 34-kDa protein coupled to Sepharose CL-4B was used to purify the pp60src substrate to homogeneity in milligram quantities. Both the purified 34-kDa protein and the monoclonal antibody are currently being used in studies aimed at elucidating the structure and function of this pp60src target.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6305989

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  16 in total

1.  Epidermal growth factor (urogastrone)-mediated phosphorylation of a 35-kDa substrate in human placental membranes: relationship to the beta subunit of the guanine nucleotide regulatory complex.

Authors:  K A Valentine-Braun; J K Northup; M D Hollenberg
Journal:  Proc Natl Acad Sci U S A       Date:  1986-01       Impact factor: 11.205

2.  Modulation of p36 phosphorylation in human cells: studies using anti-p36 monoclonal antibodies.

Authors:  C M Isacke; I S Trowbridge; T Hunter
Journal:  Mol Cell Biol       Date:  1986-07       Impact factor: 4.272

3.  The amino-terminal region of the adenovirus serotype 5 E1a protein performs two separate functions when expressed in primary baby rat kidney cells.

Authors:  D H Smith; E B Ziff
Journal:  Mol Cell Biol       Date:  1988-09       Impact factor: 4.272

4.  Biochemical characterization of a 34-kilodalton normal cellular substrate of pp60v-src and an associated 6-kilodalton protein.

Authors:  E Erikson; H G Tomasiewicz; R L Erikson
Journal:  Mol Cell Biol       Date:  1984-01       Impact factor: 4.272

5.  Alteration of neural cell adhesion molecule (N-CAM) expression after neuronal cell transformation by Rous sarcoma virus.

Authors:  M E Greenberg; R Brackenbury; G M Edelman
Journal:  Proc Natl Acad Sci U S A       Date:  1984-02       Impact factor: 11.205

6.  Isolation of a cDNA clone complementary to sequences for a 34-kilodalton protein which is a pp60v-src substrate.

Authors:  H G Tomasiewicz; R Cook-Deegan; D M Chikaraishi
Journal:  Mol Cell Biol       Date:  1984-09       Impact factor: 4.272

Review 7.  Annexin II tetramer: structure and function.

Authors:  D M Waisman
Journal:  Mol Cell Biochem       Date:  1995 Aug-Sep       Impact factor: 3.396

8.  Vector expression of adenovirus type 5 E1a proteins: evidence for E1a autoregulation.

Authors:  D H Smith; D M Kegler; E B Ziff
Journal:  Mol Cell Biol       Date:  1985-10       Impact factor: 4.272

9.  The regulatory chain in the p36-kd substrate complex of viral tyrosine-specific protein kinases is related in sequence to the S-100 protein of glial cells.

Authors:  V Gerke; K Weber
Journal:  EMBO J       Date:  1985-11       Impact factor: 11.598

10.  Identity of p36K phosphorylated upon Rous sarcoma virus transformation with a protein purified from brush borders; calcium-dependent binding to non-erythroid spectrin and F-actin.

Authors:  V Gerke; K Weber
Journal:  EMBO J       Date:  1984-01       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.